{"id":"W3007752132","doi":"10.1182/bloodadvances.2019000885","title":"A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Rivaroxaban; Edoxaban; Medicine; Anticoagulant; Bolus (digestion); Apixaban; Placebo; Pharmacology; Anesthesia; Internal medicine; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001187826,0.0000825776,0.0003567688,0.00008961978,0.0000207029,0.000003398912,0.0000324325,0.00002394931,0.000008282141],"category_scores_gemma":[0.0001528283,0.00007365191,0.00003852542,0.0001925645,0.00003082825,0.0001273354,0.00002002579,0.00003456732,2.392202e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000004673509,"about_ca_system_score_gemma":0.00001735215,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003698259,"about_ca_topic_score_gemma":0.00004701369,"domain_scores_codex":[0.9992058,0.00002624653,0.000353191,0.0001705528,0.0001462853,0.00009796175],"domain_scores_gemma":[0.9995771,0.00009198021,0.0001526659,0.00008153913,0.00004201875,0.00005470294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003680441,0.0003896675,0.9817364,0.0007342788,0.0001096964,0.00000416733,0.002369288,0.0001598335,0.004350791,0.000180844,0.00005145364,0.006233117],"study_design_scores_gemma":[0.1723102,0.04951355,0.7237369,0.0003674848,0.00175631,0.000006690086,0.01741749,0.01093821,0.008375129,0.0004597002,0.0145241,0.0005942842],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963545,0.0008956225,0.0002275842,0.001257269,0.00005377124,0.001123695,0.00001158171,0.00001472092,0.00006124502],"genre_scores_gemma":[0.9984227,0.0001151307,0.001174042,0.00009052439,0.0001417844,0.000003223322,0.0000183169,0.000008030886,0.00002618175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2579996,"threshold_uncertainty_score":0.3003438,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07116701488639715,"score_gpt":0.3844771447968021,"score_spread":0.3133101299104049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}